#3196
Phase 2 study of cisplatin and everolimus in patients with metastatic extrapulmonary neuroendocrine carcinoma (NEC)
Introduction:
Extrapulmonary NEC (EP-NEC) are an aggressive subgroup of neuroendocrine neoplasms (NEN). Advanced EP-NEC are generally treated with platinum-based cytotoxic regimens. Although highly responsive to cytotoxic therapies, recurrence occurs frequently and rapidly, with a poor prognosis and lack of further treatment options. Genetic alterations in the mTOR pathway have been identified in NEN, providing a rationale for treatment with the mTOR inhibitor everolimus.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Levy S
Authors:
Levy S,
Verbeek W,
Eskens F,
de Groot D,
Van Leerdam M,
Keywords:
phase 2,
extrapulmonary NEC,
everolimus,
cisplatin,
#3103
Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms
Introduction:
18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Veenstra E
Authors:
Veenstra E,
de Groot D,
Brouwers A,
Walenkamp A,
Noordzij W,
Keywords:
neuroendocrine tumor,
PET,
tracer,
18F-DOPA,
68GA-DOTA-TOC,
tumor marker,
carbidopa,